Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 30,2020 No.3Detail

The importance of bismuth-containing quadruple therapy in Helicobacter pylori eradication in an era of increasing antibiotic resistance

Published on Jun. 21, 2020Total Views: 9084 timesTotal Downloads: 2647 timesDownloadMobile

Author: Yi HU 1 Yuan ZHUANG 2 Nong-Hua LYU 1*

Affiliation: 1. Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nan-chang 330006, P.R. China 2. Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center for Immunological Products, School of Pharmacy, Army Medical University, Chongqing 400038, P.R. China

Keywords: Helicobacter pylori Antibiotic resistance Bismuth Efficacy

DOI: 10.12173/j.issn.1004-5511.2020.03.06

Reference: Hu Y, Zhuang Y, Lyu NH. The importance of bismuth-containing quadruple therapy in Helicobacter pylori eradication in an era of increasing antibiotic resistance[J]. Yixue Xinzhi Zazhi, 2020, 30(3): 179-183. DOI: 10.12173/j.issn.1004-5511.2020.03.06.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Approximately half of the global population is infected with Helicobacter pylori (Hp). Currently, the main challenge in the field of Hp is that the antibiotic resistance of Hp is increased, leading to the decreased efficacy of regimens. The prevalence of Hp primary resistance to clarithromycin, metronidazole, and levofloxacin is above the alarming level in most areas of the world. Moreover, Hp was defined as a high-priority bacterium in the World Health Organization (WHO) priority list of antibiotic-resistant bacteria. Bismuth has several advantages, including low resistance rate, safe and improving the eradication rate in Hp resistant strains. Therefore, bismuth-containing quadruple therapy is recommended as the first-line regimens by the international Hp consensus report. This article emphasizes the importance of bismuth-containing quadruple therapy in Hp eradication in an era of increasing antibiotic resistance through reviewing the recently published Hp consensus report and relevant clinical articles.

Full-text
Please download the PDF version to read the full text: download
References

1.  Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits[J]. Gastroenterology, 2015, 148(4): 719-731.e3. DOI: 10.1053/j.gastro.2015.01.040.

2.  Hooi J, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis[J]. Gastroenterology, 2017, 153(2): 420-429. DOI: 10.1053/j.gastro.2017.04.022.

3.  Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection[J]. Aliment Pharmacol Ther, 2018, 47(7): 868-876. DOI: 10.1111/apt.14561.

4.  Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization regions[J]. Gastroenterology, 2018, 155(5): 1372-1382.e17. DOI:10.1053/j.gastro.2018.07.007.

5.  Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327. DOI: 10.1016/S1473-3099(17)30753-3.

6.  Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance[J]. Gut, 2010, 59(8): 1143-1153. DOI: 10.1136/gut.2009.192757.

7.  Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12(4): 275-278. DOI: 10.1111/j.1523-5378.2007.00518.x.

8.  Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J]. Gut, 2017, 66(1): 6-30. DOI: 10.1136/gutjnl-2016-312288.

9.  Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection[J]. Am J Gastroenterol, 2017, 112(2): 212-239. DOI: 10.1038/ajg.2016.563.

10. Liu WZ, Xie Y, Lu H, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection[J]. Helicobacter, 2018, 23(2): e12475. DOI: 10.1111/hel.12475.

11. 张宁萍, 王吉耀, 陈世耀, 等. 我国消化内科临床实践指南或共识的评价[J]. 中华消化杂志,  2019, 39(9): 613-618. DOI: 10.3760/cma.j.issn.0254-1432.2019.09.004. [Zhang NP, Wang  JY, Chen SY, et al. Evaluation of Chinese clinical practice guideline/consensus for digestive diseases[J]. Chinese Journal of Digestion, 2019, 39(9):  613-618.]

12. Sun H. Biological Chemistry of Arsenic, Antimony and Bismuth[M]. Wiley: Chichester UK, 2011.

13. Li H, Wang R, Sun H. Systems approaches for unveiling the mechanism of action of bismuth drugs: New medicinal applications beyond Helicobacter Pylori Infection[J]. Acc Chem Res, 2019, 52(1): 216-227. DOI: 10.1021/acs.accounts.8b00439.

14. Axon AT. Helicobacter pylori therapy: effect on peptic ulcer disease[J]. J Gastroenterol Hepatol, 1991, 6(2): 131-137. DOI: 10.1111/j.1440-1746.1991.tb01452.x.

15. Wermeille J, Zelger G, Cunningham M. The eradication treatments of Helicobacter pylori[J]. Pharm World Sci, 1998, 20(1): 1-17. DOI: 10.1023/a:1008638102503.

16. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy[J]. Gut, 2016, 65(5): 870-878. DOI: 10.1136/gutjnl-2015-311019.

17. McNicholl AG, O'Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg)[J]. Helicobacter, 2019, 24(5): e12630. DOI: 10.1111/hel.12630.

18. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bsmuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients[J]. Clin Gastroenterol Hepatol, 2020, 18(1): 89-98. DOI: 10.1016/j.cgh.2019.03.048.

19. Song C, Qian X, Zhu Y, et al. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice[J]. Helicobacter, 2019, 24(4): e12591. DOI: 10.1111/hel.12591.

20. Macías-García F, Bastón-Rey I, de la Iglesia-García D, et al. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial[J]. Helicobacter, 2019, 24(1): e12546. DOI: 10.1111/hel.12546.

21. Ciccaglione AF, Cellini L, Marzio L. Pylera plus ranitidine vs Pylera plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies[J]. Helicobacter,  2019, 24(5): e12606. DOI: 10.1111/hel.12606.

22. Gu L, Li S, He Y, et al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study[J]. Helicobacter, 2019, 24(4): e12594. DOI: 10.1111/hel.12594.

23. Harb AH, Chalhoub JM, Abou Mrad R, et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication[J]. Aliment Pharmacol Ther, 2015, 42(2): 131-141. DOI: 10.1111/apt.13259.

24. Lu B, Wang J, Li J, et al. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial[J]. Helicobacter,  2019, 24(2): e12566. DOI: 10.1111/hel.12566.

25. Yi DM, Yang TT, Chao SH, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study[J]. Medicine (Baltimore), 2019, 98(6): e14408.

26. Wang T, Yang X, Li Y, et al. Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study[J]. Helicobacter, 2019, 24(3): e12569. DOI: 10.1111/hel.12569.


Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us